[go: up one dir, main page]

EP0000338A2 - Dérivés de la isoxazolo(5,4-c)pyridine, leur préparation et composition pharmaceutique les contenant - Google Patents

Dérivés de la isoxazolo(5,4-c)pyridine, leur préparation et composition pharmaceutique les contenant Download PDF

Info

Publication number
EP0000338A2
EP0000338A2 EP78100191A EP78100191A EP0000338A2 EP 0000338 A2 EP0000338 A2 EP 0000338A2 EP 78100191 A EP78100191 A EP 78100191A EP 78100191 A EP78100191 A EP 78100191A EP 0000338 A2 EP0000338 A2 EP 0000338A2
Authority
EP
European Patent Office
Prior art keywords
group
hydrogen
general formula
compound
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP78100191A
Other languages
German (de)
English (en)
Other versions
EP0000338A3 (en
EP0000338B1 (fr
Inventor
Povl Krogsgaard-Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of EP0000338A2 publication Critical patent/EP0000338A2/fr
Publication of EP0000338A3 publication Critical patent/EP0000338A3/en
Application granted granted Critical
Publication of EP0000338B1 publication Critical patent/EP0000338B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • GABA gamma-aminobutyric acid
  • CNS central nervous system
  • muscimol of the formula (a substance found in fly amanita (Amanita muscaria)) has various interesting pharmacological properties and especially shows an inhibition of motoric functions. Later, it was reported that muscimol is a very potent GABA agonist with respect to bicuculline--sensitive postsynaptic receptors (Johnston et al., Biochem. Pharmacol.
  • agents influencing the GABA system are therefore under consideration and research for the therapeutical treatment of such GABA system malfunction-related diseases. It is also under consideration to administer agents influencing the GABA system against diseases in which malfunctions of the pituitary hormones are involved, e.g. diseases where a decreased secretion of prolactin is involved, and it is, furthermore, contemplated that such agents may be useful against artereoschlerotic diseases in the brain where a vasodilatation is desired.
  • muscimol has toxic effects, such as narcotic effects (derealisation and depersonalisation), and the difference between the effective dose and the toxic dose of muscimol is very small (Arzneiffenaba, 1968, 18, 311 - 315), which may limit or prevent the therapeutic use of muscimol.
  • various muscimol-analogues or muscimol-like substances have been synthesized and tested (P.
  • the present invention relates to novel compounds showing GABA--related activity, to salts thereof with acids or bases, and to pharmaceutical compositions containing the novel compounds or a salt thereof as an active ingredient. Moreover, the present invention relates to methods for the preparation of the novel compounds and salts thereof and to a method for the treatment of neurological and psychiatrical disorders, such as epilepsy, parkinsonism, schizophrenia and Huntington's chorea, or diseases in which malfunctions of the pituitary hormones are involved, or artereoschlerotic diseases in the brain where a vasodilatation is desired, by administering a therapeutically active amount of the novel compound or a non-toxic salt thereof to a living animal body including human beings.
  • neurological and psychiatrical disorders such as epilepsy, parkinsonism, schizophrenia and Huntington's chorea, or diseases in which malfunctions of the pituitary hormones are involved, or artereoschlerotic diseases in the brain where a vasodilatation is desired, by administer
  • the novel compound of the formula Ia (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-3-ol) is well tolerated and is a very potent GABA agonist having a very specific activity, being inactive as a GABA-uptake inhibitor. Particulars concerning the activity of this compound are given in the section "Test Results” below.
  • the potent, specific GABA agonist activity of the compound Ia is especially remarkable on the background of the fact that the known very closely related compounds, that is, 5,6,7,8-tetrahydro-4H-isoxazolo-[4,5-c]-azepine-3-ol (P. Krogsgaard-Larsen, Acta Chem. Scand. B 31, 1977, 584 - 588, and P. Krogsgaard-Larsen and G.A.R. Johnston, J. Neurochem., 1978, 30, 1377 - 1382). 5,6,7,8-tetrahydro-4H-isoxazolo-[5,4-c]-azepine-3-ol (P.
  • the present invention is not to be limited by any theory, it is believed that the remarkable selective activity of the compound Ia is ascribable to the particular position of the nitrogen atom in the 6-membered ring in relation to the acidic hydroxy group in the 5-membered ring.
  • the present invention therefore relates to the novel compound Ia and to derivatives thereof which upon administration will be decomposed in situ to yield the parent compound Ia, in particular compounds of the general formula I wherein R" is hydrogen, acetyl or a group of the general formula VII wherein R 5 is C 1-8 alkyl; phenyl; phenyl substituted in the 4- position with halogen, lower alkoxy, or lower alkyl; or phenylalkyl such as benzyl or phenylethyl in which the phenyl group may be substituted in the 4-position with halogen, lower alkoxy, or lower alkyl; and salts thereof.
  • R" is hydrogen, acetyl or a group of the general formula VII wherein R 5 is C 1-8 alkyl; phenyl; phenyl substituted in the 4- position with halogen, lower alkoxy, or lower alkyl; or phenylalkyl such as benzyl or phenylethyl in which
  • the compounds I the only species showing pronounced GABA agonist activity in the brain is the compound Ia.
  • the groups R" which are different from hydrogen may enhance the penetration of the compounds into the brain in that they may enhance the ability of the compounds to pass the blood- brain barrier, and will thereafter be split off in situ to yield the parent compound.
  • a prolonged effect of Ia may be obtained via decomposition in situ of compounds wherein R" is different from hydrogen, to yield the parent compound.
  • lower alkyl and “lower alkoxy” designate such groups containing 1 - 4 carbon atoms.
  • the compounds of the general formula I may exist in a tautomeric form, as shown by the formula I' and in the present specification and claims, the formula I is to be understood as covering also this tautomeric form and mixtures of the two tautomeric forms.
  • salts of the compound of the formula Ia are acid addition salts thereof, such as pharmaceutically acceptable salts with inorganic acids, e.g. hydrochloric, hydrobromic, nitric, sulfuric, phosphoric acids and the like, or with organic acids, such as organic carboxylic acids, e.g. acetic, propionic, glycolic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, glucuronic, benzoic, pamoic acid and the like, or organic sulfonic acids, e.g.
  • salts may be prepared by procedures known per se, e.g. by adding the acid in question to the base, preferably in a solvent.
  • Compounds of formula I may form pharmaceutically acceptable salts with bases, such as metal salts, e.g. sodium, potassium, calcium or aluminium salts, and ammonium and substituted ammonium salts, e.g. salts of amines such as triethylamine, triethanolamine, ethylpiperidine, procaine, dibenzylamine and the like.
  • the compound Ia was tested in microelectrophoretic experiments. Experiments were performed on lumbar dorsal horn interneurones and Renshaw cells of cats anaesthetized with pentobarbitone sodium. The approximate potency of the depressant actions of the compound was assessed relative to that of GABA on the basis of electrophoretic currents required to produce equal and submaximal inhibitions of the firin of the central neurones. The inhibitory action of Ia on central neurones was antagonized by the specific GABA antagonist bicu- culline methochloride (BMC).
  • BMC bicu- culline methochloride
  • the compound Ia did not interact with the GABA uptake system at concentrations of 5 x 10 4 M, and it did not interact with the GABA metabolizing enzymes GABA:2-oxo-glutarate aminotransferase and L-glutamate 1-carboxylase at concentrations of 10 -3 M.
  • the compound Ia is a specific and very potent GABA agonist.
  • compound Ia is considerably less toxic than muscimol.
  • Ia was shown to be weaker than muscimol.
  • I a was found to be weaker than muscimol.
  • test compound is injected i.p. in the doses 0, 1/2, 1/8 and 1/32 of the determined “i.v. LD 50 ".
  • doses 0, 1/4, 1/16 and 1/64 of the determined "i.p. LD 50 " are used.
  • mice are used for each dose level.
  • isoniazide 300 mg/kg is injected s.c. This dose of isoniazide induces intermittent tonic clonic seizures within 60 minutes.
  • compound Ia has been shown to be a potent GABA agonist.
  • Compound Ia is weaker than muscimol but considerably less toxic.
  • the compounds of formula I may be prepared by
  • Compound IVa in reaction scheme I is a key intermediate in the above synthesis and in other syntheses of the compounds of the present invention. Similar key intermediates may contain other hydrolysable N-protecting groups and other lower alkyl groups, and hence, in its broad concept, this novel key intermediate of the present invention has the general formula IV in which Alk is a lower alkyl group and Z is hydrogen or an amino--protecting group readily removable, e.g. by hydrolysis, suitably a group R" (as defined above) or a trityl or formyl group.
  • Z are the following: hydrogen, methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, tert.butyloxycarbonyl, benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, trityl, formyl, acetyl.
  • novel intermediates according to the present invention are the compounds of the formulae VIIIa and IXa in reaction scheme I, and also the generic classes which they represent, which is, compounds of the general formula VIII' in which Z is as defined above, T is a group convertible, by hydrolysis, into an oxy group, e.g., an acetal group such as ethylene dioxy, and Q is a leaving group which, on reaction with hydroxylamine, forms a hydroxamic acid group, examples of Q being halogen, especially chlorine and bromine, hydroxy, the residue of an acid, the residue of an activated amide, the residue of an activated ester, lower alkoxy, and the like, and compounds of the general formula IX' in which Z and T are as defined above, and also, at the stage of compound Va (which is both a compound of the general formula I and an intermediate for the preparation of compounds of the general formula I), an intermediate may be used which in generalized form has the formula V above.
  • T is a group convertible, by hydrolysis, into an oxy group,
  • An interesting aspect of the present invention is the compound Ia as intermediate in the preparation of compounds of formula I in which R" is different from hydrogen.
  • the present invention also relates to the total sequence of synthesis stages IV ⁇ VIII' ⁇ IX' ⁇ V ⁇ I and to the final stages thereof, i.e., VIII' ⁇ IX' ⁇ V ⁇ I and IX' ⁇ V ⁇ I.
  • the conversion of ethyl l-benzyl-3-oxy-piperidine-4-carboxylate into the intermediate IV as exemplified by IVa is usually performed in lower alkanols, e.g. ethanol or ethanol/water.
  • the removal of the N-benzyl group may be effected with gaseous hydrogen in the presence of a hydrogenation catalyst, e.g. platinum, palladium or Raney nickel.
  • the alkyl 3-oxy-piperidine-4-carboxylate formed is dissolved, e.g. in water, and treated with an acid acceptor, e.g. alkali carbonate, and an ester of chloroformic acid, e.g. methyl chloroformate.
  • the temperature is kept near 0°C during the reaction.
  • the compound IV is isolated by extraction into an organic solvent followed by evaporation of the solvent.
  • the formation of the compound of formula VIII' as exemplified by the ethylene acetal VIIIa is usually performed in a solvent, e.g. benzene, which forms an azeotropic mixture with water.
  • a solvent e.g. benzene
  • the reaction is preferably carried out at reflux temperature and with a strong acid, e.g. a sulfonic acid as catalyst.
  • the hydroxamic acid IX' as exemplified by IXa is synthesized by reacting VIIIa with hydroxylamine, preferably in water or a lower alcohol, e.g. methanol and usually at a temperature between -20°C and room temperature, preferably at 0 - 10°C.
  • the compound may be isolated and purified by a manner known per se, e.g. column chromatography.
  • Q in formula VIII' is a halogen or the residue of an acid
  • the reaction is effected in the presence of a base.
  • a condensing agent e.g. dicyclohexyl carbodiimide or carbonyldiimidazole.
  • solvent an iner
  • the hydrolysis of the acetal group of IXa or, quite generally, the conversion of T in compounds of formula IX' into an oxo group, followed by cyclization to a compound of formula V as exemplified by Va may be effected by an aqueous solution of a strong acid optionally also containing acetic acid, e.g. concentrated hydrochloric acid or 70% perchloric acid at a temperature between 0°C and 100°C, preferably at 50 - 80°C.
  • the compound V may be isolated by extraction with an organic solvent or by evaporation of the water.
  • the compound can be purified by column chromatography or by crystallization.
  • Removal of the protecting group Z and/or W in compound V may be effected with a strong inorganic acid, e.g. hydrochloric or hydrobromic acid, in a solvent, e.g. glacial acetic acid or water, or a mixture of water and glacial acetic acid.
  • a strong inorganic acid e.g. hydrochloric or hydrobromic acid
  • the temperature may be kept between room temperature and the boiling point of the solvent.
  • the reaction time is usually short, e.g. less than 1 hour.
  • the Ia salt may be isolated by evaporation of the solvent.
  • the Ia salt may be transformed into Ia by treatment with a base, e.g. a tertiary amine, in a solvent, usually a mixture of water and a lower alkanol.
  • Compound Ia may be transformed into another salt as described above.
  • reaction of a compound of the general formula IV as exemplified by IVa with hydroxylamine may give a mixture of a compound of the general formula V and the corresponding isomeric compound V as exemplified by Va and VIa.
  • the reaction may be effected at a temperature between -30°C and 50°C, preferably between -30 and -lO o C.
  • the solvent is usually water or a lower alkanol or mixtures thereof.
  • reaction scheme II although yielding a mixture of two isomers, is nevertheless advantageous. It is very time-saving in that it avoids the protection of the oxo group in compounds of the general formula IV and the subsequent hydroxamic acid formation.
  • the compounds formed in the reaction of IV with hydroxylamine, as exemplified by Va and VIa, are easily separated by manners known per se, e.g. by column chromatography.
  • the introduction of the group R" may be performed by manners known per se.
  • R" is a group of the above formula VII
  • the introduction may be performed by treatment of compound Ia with the appropriate. formic acid ester of the general formula X'- -OR 5 wherein X' is a leaving group, especially halogen, azido, etc., in the presence of an acid acceptor, for example an alkali carbonate.
  • an acid acceptor for example an alkali carbonate.
  • the BOC-derivative can be made by means of tert.butyl azidoformate.
  • R" is acetyl
  • a reactive derivative of acetic acid e.g. acetyl chloride or acetanhydride may be used for the introduction of the group R".
  • the compounds of the formula I, and salts thereof may be formulated for administration in any convenient way by analogy with other pharmaceuticals.
  • compositions comprising the compounds of the invention may be in the form of pharmaceutical preparations, e.g. in solid, semisolid or liquid form, which contain the active compound of the invention in admixture with a pharmaceutical organic or inorganic carrier or excipient suitable for enteral or parenteral application.
  • the active ingredient may, e.g., be formulated with the usual carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, aqueous suspensions and other suitable administration forms.
  • Examples of carriers are glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, and other carriers suitable for use in manufacturing compositions in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening, colouring, flavouring, and preservative agents can be contained in the composition of this invention.
  • the active compound is included in the compositions of the invention in an amount sufficient to produce the desired therapeutical effect upon administration.
  • the dosage or therapeutically effective quantity of the compound varies and also depends upon the age and condition of each individual patient being treated.
  • a preferred tablet or capsule formulation for oral administration contains 0.1 - 200 mg, preferably 1 - 100, especially 5 - 50, mg of a compound of the formula I or a salt thereof per unit dosage which may be administeret 1 - 4 times per day or as a sustained release composition.
  • Injection preparations preferably contain 0.1 - 200 mg, preferably 1 - 100, especially 5 - 50, mg of a compound of the formula I or a salt thereof per unit dosage.
  • a preferred injected dose is about 0.5 to 2 ml.
  • the invention also relates to the use of the compounds of the general formula I and salts thereof in medicaments for treating GABA system malfunction-related diseases, and a process of treating GABA system malfunction-related diseases in human beings by administering, to the human being, an effective dose of a compound of the general formula I, or a salt thereof.
  • compositions and the above-mentioned uses it may be suitable or preferred to combine the compounds of the general formula I or a salt thereof with minor tranquillizers such as benzodiazepines or neuroleptics, for example butyrophenones such as haloperidol, phenothiazines such as chloropromazine, thioxanthene, and the like.
  • minor tranquillizers such as benzodiazepines or neuroleptics, for example butyrophenones such as haloperidol, phenothiazines such as chloropromazine, thioxanthene, and the like.
  • the neuroleptics are suitably administered in their effective amounts or, in a preferred embodiment in lower amounts than the amounts in which they would be effective when used alone.
  • IXa (1.9 g; 29%) as a crystalline and TLC-pure substance [R F : 0.23; eluent: ethyl acetate-methanol-formic acid (90:9:1)].
  • An analytical sample was recrystallized (ethanol-benzene) to give IXa as colourless crystals, m.p. 150.0--152.0°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
EP78100191A 1977-06-20 1978-06-19 Dérivés de la isoxazolo(5,4-c)pyridine, leur préparation et composition pharmaceutique les contenant Expired EP0000338B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20
GB2574077 1977-06-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP80106497.3 Division-Into 1980-10-23
EP80106498.1 Division-Into 1980-10-23

Publications (3)

Publication Number Publication Date
EP0000338A2 true EP0000338A2 (fr) 1979-01-24
EP0000338A3 EP0000338A3 (en) 1979-06-27
EP0000338B1 EP0000338B1 (fr) 1981-11-25

Family

ID=10232513

Family Applications (4)

Application Number Title Priority Date Filing Date
EP78100191A Expired EP0000338B1 (fr) 1977-06-20 1978-06-19 Dérivés de la isoxazolo(5,4-c)pyridine, leur préparation et composition pharmaceutique les contenant
EP78100190A Withdrawn EP0000167A1 (fr) 1977-06-20 1978-06-19 Acides 1,2,3,6-tétrahydroisonicotiniques et leurs dérivés, méthodes et produits de départ pour leur préparation, et leurs compositions pharmaceutiques.
EP80106498A Withdrawn EP0028017A1 (fr) 1977-06-20 1978-06-19 Dérivés de l'acide 3-pipéridinone-4-carboxylique
EP80106497A Withdrawn EP0027279A1 (fr) 1977-06-20 1978-06-19 Isoxazolo(5,4-c)pyridines

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP78100190A Withdrawn EP0000167A1 (fr) 1977-06-20 1978-06-19 Acides 1,2,3,6-tétrahydroisonicotiniques et leurs dérivés, méthodes et produits de départ pour leur préparation, et leurs compositions pharmaceutiques.
EP80106498A Withdrawn EP0028017A1 (fr) 1977-06-20 1978-06-19 Dérivés de l'acide 3-pipéridinone-4-carboxylique
EP80106497A Withdrawn EP0027279A1 (fr) 1977-06-20 1978-06-19 Isoxazolo(5,4-c)pyridines

Country Status (14)

Country Link
US (2) US4278676A (fr)
EP (4) EP0000338B1 (fr)
JP (2) JPS5436275A (fr)
AT (1) AT368505B (fr)
AU (2) AU3724478A (fr)
CA (1) CA1107736A (fr)
DK (2) DK270278A (fr)
ES (2) ES470912A1 (fr)
FI (2) FI64376C (fr)
IE (1) IE47200B1 (fr)
IT (2) IT1159739B (fr)
NO (3) NO782128L (fr)
NZ (1) NZ187615A (fr)
ZA (2) ZA783492B (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494691A1 (fr) * 1980-11-27 1982-05-28 Kefalas As Nouvelles 2-acyl 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinones-3 utiles comme medicaments, procede de leur preparation et compositions pharmaceutiques les contenant
FR2494692A1 (fr) * 1980-11-27 1982-05-28 Kefalas As Nouvelles 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridines 3-substituees, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0126654A1 (fr) * 1983-05-24 1984-11-28 H. Lundbeck A/S Dérivés de la tétrahydroisoxazolo[4,5-c]pyridine et leur préparation
EP0350051A1 (fr) * 1988-07-06 1990-01-10 Bristol-Myers Squibb Company Dérivés de THAZ pour l'activation de fonctions cérébrales
WO2005023820A1 (fr) * 2003-09-05 2005-03-17 H. Lundbeck A/S Procede de production de thip
WO2005073237A3 (fr) * 2004-01-30 2005-10-20 Merck Sharp & Dohme Formes polymorphes d'un agoniste gabaa
WO2006118897A1 (fr) * 2005-04-29 2006-11-09 H.Lundbeck A/S Formes de sels acides et de sels basiques de gaboxadol
EP1848420A4 (fr) * 2005-01-28 2008-01-23 Merck & Co Inc Formes polymorphes d'un agoniste gabaa
EP2145620A2 (fr) 2003-06-25 2010-01-20 H. Lundbeck A/S Gaboxadole pour le traitement de la dépression et d'autres troubles affectifs
US9339495B2 (en) 2014-06-06 2016-05-17 Ovid Therapeutics Inc Methods of increasing tonic inhibition and treating secondary insomnia
WO2016150953A1 (fr) 2015-03-24 2016-09-29 H. Lundbeck A/S Fabrication de 4,5,6,7-tétrahydroisozaxolo[5,4-c] pyridine-3-ol
WO2017015049A1 (fr) 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Méthodes de traitement de troubles du développement avec le gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
WO2018144827A1 (fr) 2017-02-03 2018-08-09 Ovid Therapeutics Inc. Utilisation de gaboxadol dans le traitement des acouphènes
US10363246B1 (en) 2016-08-11 2019-07-30 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083378A1 (fr) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tétrahydronicotinamides, leur procédé de préparation, et les compositions pharmaceutiques les contenant
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
EP2343073A3 (fr) * 2003-12-11 2011-10-12 Sepracor Inc. Combinaison de sédatif et modulateur neurotransmetteur et procédés d'amélioration de la qualité du sommeil et de traitement de la dépression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
WO2005063297A2 (fr) * 2003-12-24 2005-07-14 Sepracor Inc. Polytherapie a base de melatonine destinee a ameliorer la qualite du sommeil
EP1742624B1 (fr) * 2004-02-18 2010-01-06 Sepracor, Inc. Therapie combinee avec agonistes de la dopamine et des sedatives pour ameliorer la qualite du sommeil
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP2258357A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
CA2651862A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese induite par le recepteur 5ht
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
MX2021005992A (es) 2018-11-21 2021-09-14 Certego Therapeutics Inc Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACTA CHEMICA SCANDINAVICA B28, Pages 533-38 (1974) *
CHEMICAL ABSTRACTS 84, 159505z (1976) *
CHEMICAL ABSTRACTS 88, 37672p (1978) & Acta Chemica Scandinavica B31 (7), 584-8 (1977) *
NATUR (London) 268 (5615) 53-5 (1977) *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2494692A1 (fr) * 1980-11-27 1982-05-28 Kefalas As Nouvelles 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridines 3-substituees, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2494691A1 (fr) * 1980-11-27 1982-05-28 Kefalas As Nouvelles 2-acyl 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinones-3 utiles comme medicaments, procede de leur preparation et compositions pharmaceutiques les contenant
EP0126654A1 (fr) * 1983-05-24 1984-11-28 H. Lundbeck A/S Dérivés de la tétrahydroisoxazolo[4,5-c]pyridine et leur préparation
EP0350051A1 (fr) * 1988-07-06 1990-01-10 Bristol-Myers Squibb Company Dérivés de THAZ pour l'activation de fonctions cérébrales
EP2145620A2 (fr) 2003-06-25 2010-01-20 H. Lundbeck A/S Gaboxadole pour le traitement de la dépression et d'autres troubles affectifs
US7371863B2 (en) 2003-09-05 2008-05-13 H. Lundbeck A/S Method for manufacture of THIP
WO2005023820A1 (fr) * 2003-09-05 2005-03-17 H. Lundbeck A/S Procede de production de thip
AU2004270323B2 (en) * 2003-09-05 2010-01-07 H. Lundbeck A/S Method for the manufacture of THIP
WO2005073237A3 (fr) * 2004-01-30 2005-10-20 Merck Sharp & Dohme Formes polymorphes d'un agoniste gabaa
EA009413B1 (ru) * 2004-01-30 2007-12-28 Мерк Шарп Энд Домэ Лимитед Полиморфные формы габоксадола, агониста gaba
EP2042505A1 (fr) 2004-01-30 2009-04-01 H. Lundbeck A/S Formes polymorphes d'un agoniste GABAa
US7262300B2 (en) 2004-01-30 2007-08-28 Merck Sharp & Dohme Ltd. Polymorphic forms of a GABAA agonist
CN1914212B (zh) * 2004-01-30 2010-10-06 H.隆德贝克有限公司 Gabaa激动剂的多晶型
US8236958B2 (en) 2004-01-30 2012-08-07 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
EP1848420A4 (fr) * 2005-01-28 2008-01-23 Merck & Co Inc Formes polymorphes d'un agoniste gabaa
EP2292222A1 (fr) 2005-01-28 2011-03-09 H. Lundbeck A/S Formes polymorphes d'un agoniste GABAA
US8022084B2 (en) 2005-01-28 2011-09-20 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
US8193216B2 (en) 2005-01-28 2012-06-05 H. Lundbeck A/S Polymorphic forms of a GABAA agonist
EP1906953A4 (fr) * 2005-04-29 2009-05-20 Lundbeck & Co As H Formes de sels acides et de sels basiques de gaboxadol
WO2006118897A1 (fr) * 2005-04-29 2006-11-09 H.Lundbeck A/S Formes de sels acides et de sels basiques de gaboxadol
US9339495B2 (en) 2014-06-06 2016-05-17 Ovid Therapeutics Inc Methods of increasing tonic inhibition and treating secondary insomnia
US11278529B2 (en) 2014-06-06 2022-03-22 Ovid Therapeutics Inc. Methods for treating aggression associated with Alzheimer's disease
US9446028B2 (en) 2014-06-06 2016-09-20 Ovid Therapeutics Inc Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome
US9801864B2 (en) 2014-06-06 2017-10-31 Ovid Therapeutics Inc Methods of increasing tonic inhibition and treating secondary insomnia
US9744159B2 (en) 2014-06-06 2017-08-29 Ovid Therapeutics Inc Methods of treatment Rett syndrome
WO2016150953A1 (fr) 2015-03-24 2016-09-29 H. Lundbeck A/S Fabrication de 4,5,6,7-tétrahydroisozaxolo[5,4-c] pyridine-3-ol
US12465597B2 (en) * 2015-07-17 2025-11-11 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2017015049A1 (fr) 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Méthodes de traitement de troubles du développement avec le gaboxadol
US11096929B2 (en) 2015-07-17 2021-08-24 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP4541420A2 (fr) 2015-07-17 2025-04-23 Ovid Therapeutics Inc. Méthodes de traitement de troubles du développement avec du gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20230071127A1 (en) * 2015-07-17 2023-03-09 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3586845A1 (fr) 2016-08-11 2020-01-01 Ovid Therapeutics, Inc. Compositions pour le traitement du tremblement essentiel
US10363246B1 (en) 2016-08-11 2019-07-30 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
EP4233861A2 (fr) 2016-08-11 2023-08-30 Ovid Therapeutics, Inc. Compositions pour le traitement du tremblement essentiel
US10188635B2 (en) 2017-02-03 2019-01-29 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of tinnitus
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2018144827A1 (fr) 2017-02-03 2018-08-09 Ovid Therapeutics Inc. Utilisation de gaboxadol dans le traitement des acouphènes
US10813918B2 (en) 2017-08-04 2020-10-27 Ovid Therapeutics Inc. Use of Gaboxadol in the treatment of diabetes and related conditions
US11291658B2 (en) 2017-08-04 2022-04-05 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US11090293B2 (en) 2018-09-20 2021-08-17 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder

Also Published As

Publication number Publication date
FI781954A7 (fi) 1978-12-21
AU3724478A (en) 1980-01-03
JPS5436275A (en) 1979-03-16
IE47200B1 (en) 1984-01-11
EP0000338A3 (en) 1979-06-27
IE781234L (en) 1978-12-20
AU3729878A (en) 1980-01-03
AU521040B2 (en) 1982-03-11
DK270278A (da) 1978-12-21
DK270378A (da) 1978-12-21
ES470912A1 (es) 1979-02-01
FI781955A7 (fi) 1978-12-21
EP0000167A1 (fr) 1979-01-10
NO792839L (no) 1978-12-21
EP0028017A1 (fr) 1981-05-06
CA1107736A (fr) 1981-08-25
ATA448678A (de) 1982-02-15
IT7868450A0 (it) 1978-06-20
FI64376C (fi) 1983-11-10
NO152049B (no) 1985-04-15
AT368505B (de) 1982-10-25
EP0000338B1 (fr) 1981-11-25
FI64376B (fi) 1983-07-29
IT1159739B (it) 1987-03-04
IT7868449A0 (it) 1978-06-20
NO152049C (no) 1985-07-24
NO782127L (no) 1978-12-21
NZ187615A (en) 1981-12-15
ES470913A1 (es) 1979-02-01
US4278676A (en) 1981-07-14
NO782128L (no) 1978-12-21
JPS5436290A (en) 1979-03-16
US4301287A (en) 1981-11-17
EP0027279A1 (fr) 1981-04-22
ZA783492B (en) 1979-06-27
ZA783493B (en) 1979-06-27

Similar Documents

Publication Publication Date Title
EP0000338B1 (fr) Dérivés de la isoxazolo(5,4-c)pyridine, leur préparation et composition pharmaceutique les contenant
US4996210A (en) Heterocyclic spiro compounds and methods for preparing the same
KR0160979B1 (ko) 진통제로서 유용한 n-페닐-n-(4-피페리디닐)아미드
US6187782B1 (en) Morphinane derivatives and medicinal use thereof
IE850103L (en) Xanthine derivatives
PT96405B (pt) Processo para a preparacao de derivados da 3-aminopiperidina e de heterociclos afins contendo azoto
SU1308196A3 (ru) Способ получени 5,11-дигидро-11- @ (1-метил-4-пиперидинил)-амино @ -карбонил @ -6 @ -дибенз ( @ , @ )азепин-6-она или его солей
CA2158952C (fr) Morpholine substituee en 2 et derives thiomorpholine utilises comme antagonistes du gaba-b
US3864348A (en) 1-Oxa-3,8-diaza spiro (4,5) decane compounds
US4758559A (en) Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors
EP0126654B1 (fr) Dérivés de la tétrahydroisoxazolo[4,5-c]pyridine et leur préparation
CS203940B2 (en) Process for preparing aryloktahydropyridines
US4235921A (en) Treating muscular spasms and convulsions with 3-azabicyclo[3.1.0]hexanes
CA1125288A (fr) Composes heterocycliques qui sont des antagonistes de gaba, et leur preparation
CA1148150A (fr) Phenylmorphanes, produits intermediaires et methode de preparation
US4495178A (en) Enkephalin analogs
US4609657A (en) Ergot peptide alkaloid derivatives, processes for their preparation and pharmaceutical compositions containing them
US4332810A (en) N-(Substituted)-2,5-ethano-8-hydroxy (or methoxy)-1,2,3,4,5,6-hexahydro-3 (or 4)-benzazocine centrally-acting analgesics
US4376779A (en) N-(Substituted)-2-aza-2'-hydroxy-5,6-benzotricyclo[6.3.01,8.04,11 ] undecane centrally-acting analgesics
Chignell et al. Structures Related to Morphine. XXVIII. 1 Alternative Syntheses of α-and β-2, 9-Dimethyl-2'-hydroxy-5-propyl-6, 7-benzomorphan
EP0020885A1 (fr) Dérivés de 2-hydroxy-6,9-méthano-11-amino-5,6,7,8,9,10-hexahydro-benzocyclooctène, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4113877A (en) Substituted 2-aminomethylphenyl sulfamates
US4341904A (en) Derivatives of 2-hydroxy-6,9-methano-11-amino-5,6,7,8,9,10-hexahydro-benzocyclooctene
CA1267898A (fr) Derives de substitution d'acide benzoique-piperidylamides a pont alcoylene
GB2065113A (en) Ergoline derivatives, their production and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

17P Request for examination filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): BE CH DE FR GB LU NL SE

REF Corresponds to:

Ref document number: 2861342

Country of ref document: DE

Date of ref document: 19820128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19820630

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19830609

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19840612

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19840629

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19840630

Year of fee payment: 7

Ref country code: BE

Payment date: 19840630

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19840730

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19860630

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19870620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Effective date: 19870630

BERE Be: lapsed

Owner name: H. LUNDBECK & CO. A/S

Effective date: 19870630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19880101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19880226

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19880301

GBPC Gb: european patent ceased through non-payment of renewal fee
REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19881117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19890630

EUG Se: european patent has lapsed

Ref document number: 78100191.2

Effective date: 19880711

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT